NLS Pharmaceutics (NLSP) News Today $0.19 -0.01 (-5.00%) (As of 07/26/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 November 2021 October 2021 September 2021 August 2021 Time Period July 26 at 4:55 AM | seekingalpha.comNLSP NLS Pharmaceutics AGJune 20, 2024 | investorplace.comWhy Is NLS Pharmaceutics (NLSP) Stock Down 23% Today?June 18, 2024 | investorplace.comWhy Is NLS Pharmaceutics (NLSP) Stock Up 163% Today?May 28, 2024 | stockhouse.comNLS Pharmaceutics Reports Positive Results from Study KO-874 on Mazindol's Neuroprotective Effects in Narcoleptic-like Rat ModelMay 24, 2024 | finanznachrichten.deNLS Pharmaceutics AG: NLS Pharmaceutics Announces Receipt of Additional Staff Delisting Determination from NasdaqMay 24, 2024 | finance.yahoo.comNLS Pharmaceutics Announces Receipt of Additional Staff Delisting Determination from NasdaqMarch 22, 2024 | finanznachrichten.deNLS Pharmaceutics AG: NLS Pharmaceutics Announces Closing of $1.75 Million Registered Direct OfferingMarch 20, 2024 | finanznachrichten.deNLS Pharmaceutics AG: NLS Pharmaceutics Secures Exclusive Global License for Next-Generation Non-Sulfonamide Dual Orexin Agonist PlatformMarch 20, 2024 | finanznachrichten.deNLS Pharmaceutics AG: NLS Pharmaceutics Announces $1.75 Million Registered Direct OfferingMarch 14, 2024 | finanznachrichten.deNLS Pharmaceutics AG: NLS Pharmaceutics to Participate in the BIO-EUROPE Springtime Partnering EventMarch 11, 2024 | finanznachrichten.deNLS Pharmaceutics AG: Nasdaq Accepts NLS Pharmaceutics' Plan to Regain Listing ComplianceMarch 11, 2024 | finance.yahoo.comNasdaq Accepts NLS Pharmaceutics’ Plan to Regain Listing ComplianceFebruary 23, 2024 | finanznachrichten.deNLS Pharmaceutics AG: NLS Pharmaceutics Submits Plan to Regain Listing Compliance With NasdaqFebruary 14, 2024 | seekingalpha.comNLSP NLS Pharmaceutics Ltd.January 20, 2024 | finance.yahoo.comNotice of Deficiency with Nasdaq Continued Listing RequirementsJanuary 12, 2024 | finanznachrichten.deNLS Pharmaceutics AG: Notice of Deficiency with Nasdaq Continued Listing RequirementsDecember 23, 2023 | benzinga.comNLS Pharmaceutics Stock (NASDAQ:NLSP) Insider TradesDecember 21, 2023 | morningstar.comNLS Pharmaceutics Ltd Ordinary SharesDecember 5, 2023 | benzinga.comNLS Pharmaceutics Stock (NASDAQ:NLSP) Dividends: History, Yield and DatesDecember 1, 2023 | finance.yahoo.comNLS Pharmaceutics Announces Exclusive Option Agreement to Develop and Commercialize Next Generation Dual Orexin Agonist Platform of Aexon Labs, Inc.November 27, 2023 | finanznachrichten.deNLS Pharmaceutics AG: NLS Pharmaceutics to Participate in the Oppenheimer Sleep Disorders Summit: Deep Dive into Narcolepsy and Idiopathic HypersomniaNovember 21, 2023 | morningstar.comNLS Pharmaceutics Ltd Ordinary Shares NLSPNovember 16, 2023 | msn.comWhy NLS Pharmaceutics (NLSP) Stock Is Down 40% TodayNovember 16, 2023 | finance.yahoo.comNLS Pharmaceutics Announces Selection of Strategic Partner and Securing a Bridge LoanOctober 19, 2023 | finance.yahoo.comNLS Pharmaceuticals to Reschedule Company Update on Strategic DiscussionsOctober 12, 2023 | finanznachrichten.deNLS Pharmaceutics AG: NLS Pharmaceutics Announces Company Update on Strategic PartnershipsOctober 12, 2023 | finance.yahoo.comNLS Pharmaceutics Announces Company Update on Strategic PartnershipsOctober 5, 2023 | msn.comNLS Pharmaceutics (NLSP) Price Target Increased by 24.47% to 9.95September 14, 2023 | msn.comMaxim Group Downgrades NLS Pharmaceutics (NLSP)August 28, 2023 | benzinga.comNLS Pharmaceutics CEO Highlights Progress And Plans For Advancing Rare CNS Disorder Therapies In Shareholder LetterJuly 3, 2023 | finance.yahoo.comNLS Pharmaceutics to Proceed with Phase 3 Clinical Program (AMAZE) for Mazindol ER for the Treatment of Narcolepsy Following FDA Review and IRB Approval of the Full Study ProtocolJuly 2, 2023 | finanznachrichten.deNLS Pharmaceutics AG: NLS Pharmaceutics Company Update and Webcast Today PostponedJune 30, 2023 | finance.yahoo.comNLS Pharmaceutics Releases the Results from its Annual General MeetingJune 30, 2023 | finance.yahoo.comNLS Pharmaceutics Company Update and Webcast Today PostponedJune 19, 2023 | finanznachrichten.deNLS Pharmaceutics AG: NLS Pharmaceutics Announces Company Update WebcastJune 19, 2023 | finance.yahoo.comCORRECTION FROM SOURCE: NLS Pharmaceutics to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-VestJune 15, 2023 | markets.businessinsider.comNLS Pharmaceutics (NLSP) Receives a Buy from Maxim GroupJune 15, 2023 | finanznachrichten.deNLS Pharmaceutics AG: NLS Pharmaceutics to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-VestJune 15, 2023 | finance.yahoo.comNLS Pharmaceutics Announces Company Update WebcastJune 15, 2023 | finance.yahoo.comNLS Pharmaceutics to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-VestJune 14, 2023 | finance.yahoo.comNLS Pharmaceutics Announces Positive Safety Data From In Vitro CYP450 and Transporter Mediated Drug-Drug Interaction Studies of MazindolMay 8, 2023 | finanznachrichten.deNLS Pharmaceutics AG: NLS Pharmaceutics Appoints Keith Harrison Dewedoff as Interim Chief Financial OfficerMay 8, 2023 | msn.comNLS Pharmaceutics appoints Keith Harrison Dewedoff as interim CFO; stock slumps ~13%May 8, 2023 | finance.yahoo.comNLS Pharmaceutics Appoints Keith Harrison Dewedoff as Interim Chief Financial OfficerMay 4, 2023 | finanznachrichten.deNLS Pharmaceutics AG: NLS Pharmaceutics Presents Latest Clinical and Preclinical Data at SLEEP 2023May 4, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Ionis Pharmaceuticals (IONS), Fate Therapeutics (FATE) and NLS Pharmaceutics (NLSP)May 4, 2023 | finance.yahoo.comNLS Pharmaceutics Presents Latest Clinical and Preclinical Data at SLEEP 2023May 2, 2023 | finance.yahoo.comNLS Pharmaceutics Receives Green Light from the U.S. FDA to Proceed with Phase 3 Clinical Program (AMAZE) for Quilience(R) (Mazindol ER) for the Treatment of NarcolepsyApril 25, 2023 | finanznachrichten.deNLS Pharmaceutics AG: NLS Pharmaceutics Presents Latest Preclinical Pipeline Data at American Society of Clinical PsychopharmacologyApril 25, 2023 | finance.yahoo.comNLS Pharmaceutics Presents Latest Preclinical Pipeline Data at American Society of Clinical Psychopharmacology Get NLS Pharmaceutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NLSP and its competitors with MarketBeat's FREE daily newsletter. Email Address We’re in a code red crisis and 99% of Americans are clueless (Ad)Folks, it's 2024… Things that we used to rely on - are failing us. Take the phasing out of fossil fuels… Matched with the destruction of oil refineries around the world… And the outright failure of solar and wind technologies… But there is just one solution… And right now governments around the world are stockpiling this resource at the fastest rate in DECADES! And how YOU can prepare for the next 2024 BOOM here! NLSP Media Mentions By Week NLSP Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NLSP News Sentiment▼0.960.62▲Average Medical News Sentiment NLSP News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NLSP Articles This Week▼30▲NLSP Articles Average Week Get NLS Pharmaceutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NLSP and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Fortress Biotech News Mainz Biomed News SNDL News TC Biopharm News Aditxt News Exicure News Palisade Bio News Plus Therapeutics News Trevi Therapeutics News Harmony Biosciences News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:NLSP) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NLS Pharmaceutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share NLS Pharmaceutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
